Gastroenterology and Hepatology Department, Marqués de Valdecilla University Hospital, Clinical and Translational Research in Digestive Diseases Group-IDIVAL, Santander, Cantabria, Spain.
Clin Drug Investig. 2022 Jun;42(Suppl 1):47-53. doi: 10.1007/s40261-022-01143-9. Epub 2022 Apr 25.
Alcohol-related liver disease (ALD) is a major healthcare/economic burden and one of the leading causes of liver transplantation. New epidemiological studies that detail the course of the disease are needed since, despite its high prevalence, it is still a stigmatised condition with underlying pathology. Alcoholic hepatitis, as the highest expression of ALD, has high morbidity. Current treatments have suboptimal results with the exception of liver transplantation. Epidemiological studies must also be developed to improve prevention and implement early diagnosis policies. It is essential to develop multidisciplinary health models that allow the liver transplantation candidate to be approached in a holistic way, both for indication and follow up. The implementation of alcohol consumption biomarkers (ethyl glucuronide, phosphatidylethanol) can assist in diagnosing and supporting recovery. There are several initiatives with new therapies that must be validated to establish their effectiveness and indication.
酒精相关性肝病（ALD）是一个主要的医疗保健/经济负担，也是肝移植的主要原因之一。由于其高患病率，ALD 仍然是一种带有潜在病理的污名化疾病，因此需要详细描述疾病过程的新流行病学研究。作为 ALD 最高表现形式的酒精性肝炎，其发病率很高。除肝移植外，目前的治疗方法效果不佳。还必须开展流行病学研究，以改善预防措施并实施早期诊断政策。开发多学科的健康模式至关重要，这些模式可以全面地对肝移植候选者进行评估，包括适应证和随访。使用酒精消耗生物标志物（乙基葡糖苷酸、磷脂酰乙醇）可以辅助诊断和支持康复。有几项新疗法的举措需要进行验证，以确定其有效性和适应证。
